Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Use of high-flow nasal cannula and noninvasive ventilation in patients with COVID-19: A multicenter observational study

Jun Duan, Baixu Chen, Xiaoyi Liu, Weiwei Shu, Wei Zhao, Ji Li, Yishi Li, Yueling Hong, Longf Fang, Ke Wang

Abstract

Background: The use of high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) in patients with COVID-19 is debated.

Methods: This study was performed in four hospitals of China from January to March 2020. We retrospectively enrolled 23 and 13 COVID-19 patients who used HFNC and NIV as first-line therapy, respectively.

Results: Among the 23 patients who used HFNC as first-line therapy, 10 experienced HFNC failure and used NIV as rescue therapy. Among the 13 patients who used NIV as first-line therapy, one (8%) used HFNC as rescue therapy due to NIV intolerance. The duration of HFNC + NIV (median 7.1, IQR: 3.5–12.2 vs. 7.3, IQR: 5.3–10.0 days), intubation rate (17% vs. 15%) and mortality (4% vs. 8%) did not differ between patients who used HFNC and NIV as first-line therapy. In total cohorts, 6 (17%) patients received intubation. Time from initiation of HFNC or NIV to intubation was 8.4 days (IQR: 4.4–18.5). And the time from initiation of HFNC or NIV to termination in patients without intubation was 7.1 days (IQR: 3.9–10.3). Among all the patients, C-reactive protein was independently associated with intubation (OR = 1.04, 95% CI: 1.01–1.07). In addition, no medical staff got nosocomial infection who participated in HFNC and NIV management.

Conclusions: In critically ill patients with COVID-19 who used HFNC and NIV as first-line therapy, the duration of HFNC + NIV, intubation rate and mortality did not differ between two groups. And no medical staff got nosocomial infection during this study.
2. Methods

This was a retrospective observational study performed in four hospitals of China from January to March 2020 (the public health clinical center of Chengdu, the Central Hospital of Dazhou, Yongchuan Hospital of Chongqing Medical University and Chongqing Public Health Medical Center). In the suspected patients, the real-time reverse transcription polymerase chain reaction (RT-PCR) assay was performed according to the guideline made by our National Health Commission [9]. The COVID-19 was confirmed by a positive RT-PCR. All the patients with a confirmed COVID-19 were candidates to our study. We enrolled all the patients who used HFNC or NIV as first-line therapy. Among the HFNC patients, 17 cases extracted from a previous study were secondarily analyzed [10]. This study was approved by the local ethics committee and institutional review board (the First Affiliated Hospital of Chongqing Medical University, No. 20200201). Given its observational nature, informed consent was waived.

The application of NIV and HFNC was in the negative pressure ward or intensive care unit (ICU). To protect the medical staff, the N95 respirator, eye protection (mask with a visor), disposable gown, disposable surgical gloves, and disposable shoe covers were provided. Before entering the ward, all the medical staffs had wore these devices and checked each other.

NIV was managed according to current guidelines and the experts’ suggestions [11-14]. Face mask was the first choice to delivery the NIV to the patients. Optimal size of the mask was selected based on the face type in each patient. Hearted humidification was provided to improve oral or nasal dryness. The initial continuous positive airway pressure (CPAP) or positive end expiratory pressure (PEEP) was 4 cm H2O. When the patient tolerated this pressure, it was gradually increased to improve the oxygenation. The initial inspiratory pressure was 8–10 cm H2O. When the patient tolerated the initial pressure, it was gradually increased to relieve dyspnea. The fraction of inspired oxygen (FiO2) was titrated to main the peripheral oxygen saturation (Spo2) more than 93%. When the NIV intolerance occurred, HFNC could be used as a rescue therapy if the patient did not require urgent intubation.

HFNC was managed also based on current consensus and the experts’ suggestions [13-15]. The temperature was set between 31 and 37 °C, the flow was set between 30 and 60 L/min, and the FiO2 was set to maintain the Spo2 more than 93%. When the HFNC failed to maintain the oxygenation or relieve dyspnea, the NIV as a rescue therapy was an alternative if the patient did not require urgent intubation.

When the respiratory distress was relieved and the oxygenation was improved, the intermittent use of NIV or HFNC was performed. We gradually increased the time of conventional oxygen therapy and shortened the duration of HFNC or NIV until it was totally weaned. When the respiratory distress and oxygenation progressively deteriorated, intubation for invasive mechanical ventilation was performed based on the criteria made by our Society of Critical Care Medicine [16]. However, the intubation was decided at the discretion of the attending physicians.

Before the use of HFNC or NIV, the demographics, vital signs, laboratory tests and the arterial blood gas tests were collected. The baseline PaO2/FiO2 was measured with the use of conventional oxygen therapy before the use of HFNC or NIV. We estimated the FiO2 as follows: FiO2 (%) = 21 + 4*fow (L/min) [17]. Using these data, the acute physiology and chronic health evaluation II (APACHE II) score and sequential organ failure assessment (SOFA) score were calculated.

Data were analyzed by statistical software (SPSS 17.0; IBM Corp., Armonk, NY). Student’s t-test was used to analyze the normally distributed continuous variables and Mann–Whitney U test was used to analyze the non-normally distributed continuous variables. Chi-squared test or Fisher’s exact test was used to analyze the categorical variables. Variables with a p value <.1 in univariate analyses were entered into logistic regression analyses to identify independent risk factors associated with intubation. The ability to predict intubation was tested by the area under the receiver operating characteristic curve (AUC). The value at maximum Youden index was selected as optimal cutoff value [18]. A p value <.05 was considered significant.

3. Results

Among all the enrolled patients, 35 cases were in the negative pressure ward and one was in the ICU. Among them, HFNC was used as first-line therapy in 23 patients and NIV in 13 patients (Fig. 1). The clinical characteristics of the HFNC and NIV patients were summarized in Table 1. The mean age was 65 ± 14 years in HFNC group and 50 ± 14 years in NIV group (p <.01). The proportion of male was 52% in HFNC group and 92% in NIV group (p = .03). There were no differences in disease severity, the proportion of comorbidity, and the level of oxygenation between the two groups. Patients in HFNC group had higher chlorine, low alanine aminotransferase (ALT) and lower total bilirubin than that in NIV group. Others laboratory tests were no differences between the two groups.

Table 2 shows the settings of the HFNC and NIV at the initial 24 h. In HFNC group, the temperature was around 35 °C, flow was around 40 L/min, and FiO2 was around 40%. In NIV group, four (31%) patients used continuous positive airway pressure (CPAP) at

![Fig. 1. The flow chart of the enrolled patients.](Image)
1–2 h of NIV but one transitioned to bi-level positive pressure ventilation at 12 h of NIV. The other 9 patients (69%) used bi-level positive pressure ventilation. At 1–2 h of NIV, the inspiratory pressure was 12 cmH2O (interquartile range [IQR]: 12–15), the positive end expiratory pressure (PEEP) or CPAP was 6 cmH2O (IQR: 6–9), and the FiO2 was 40% (IQR: 40–50%). The similar settings were used at 12 h and 24 h of NIV.

There were no differences in vital signs and arterial blood gas tests between HFNC and NIV groups except the respiratory rate (Table 3). At 1–2 h, 12 h, and 24 h, the respiratory rate was lower in HFNC group than that in NIV group. The outcomes between the two groups were summarized in Table 4. In HFNC group, 10 (43%) patients used NIV as a rescue therapy. In NIV group, one (8%) used HFNC due to NIV intolerance. There was no difference in the duration of HFNC + NIV between the patients who used HFNC and NIV as first-line therapy (Median 7.1 days, IQR: 3.5–12.2 vs. 7.3 days, IQR: 5.3–10.0, p = .67). There was also no difference in intubation rate (17% vs. 15%, p >0.99) and mortality (4% vs. 8%, p >0.99) between the two groups.

Among all the patients, 6 received intubation and 30 avoided intubation (Table 5). In multivariate analyses, only C-reactive protein was independently associated with intubation (Table 6). The AUC for prediction of intubation was 0.92 (95% confidence interval [CI]: 0.87–0.98) (Fig. 2). Using C-reactive protein of 59 mg/L as cutoff value to predict intubation, the sensitivity was 100% and specificity was 80%.

### Table 1
Clinical characteristics of the enrolled patients at initiation of HFNC and NIV

| Total cohort | HFNC | NIV | p |
|--------------|------|-----|---|
| N = 36 | N = 23 | N = 13 | |
| Age, years | 60 ± 16 | 65 ± 14 | 50 ± 14 | <0.01*
| Male (%) | 24 (67%) | 12 (52%) | 12 (92%) | 0.03
| APACHE II score | 9 ± 4 | 10 ± 5 | 8 ± 2 | 0.24
| SOFA score | 4 ± 4 | 4 ± 2 | 4 ± 1 | <0.05
| The level of PaO2/FiO2 | | | |
| >200 mmHg | 12 (33%) | 9 (39%) | 3 (23%) | 0.47
| 150–200 mmHg | 14 (39%) | 10 (44%) | 4 (31%) | 0.50
| 100–150 mmHg | 10 (28%) | 6 (17%) | 6 (46%) | 0.12
| Comorbidity | | | |
| Hypertension | 9 (25%) | 6 (26%) | 3 (23%) | >0.99
| Diabetes mellitus | 4 (11%) | 4 (14%) | 0 (0%) | 0.27
| Chronic heart disease | 6 (17%) | 6 (27%) | 0 (0%) | 0.07
| Chronic respiratory disease | 1 (3%) | 1 (4%) | 0 (0%) | <0.05
| Laboratory tests | | | |
| White blood cell counts, ×10^9/L | 6.3 ± 2.6 | 5.8 ± 2.2 | 7.2 ± 3.0 | 0.12
| Neutrophil percentage, % | 78 ± 9 | 77 ± 9 | 81 ± 8 | 0.16
| Lymphocyte count, ×10^9/L | 0.81 ± 0.36 | 0.78 ± 0.36 | 0.84 ± 0.37 | 0.63
| Platelet counts, ×10^9/L | 187 ± 101 | 176 ± 95 | 206 ± 112 | 0.39
| Hemoglobin, g/dL | 123 ± 19 | 120 ± 19 | 128 ± 14 | 0.18
| Albumin, g/L | 35 ± 4 | 35 ± 3 | 37 ± 4 | 0.08
| Potassium, mmol/L | 3.8 ± 0.5 | 3.8 ± 0.5 | 3.9 ± 0.6 | 0.56
| Sodium, mmol/L | 137 ± 5 | 138 ± 5 | 135 ± 4 | 0.14
| Chlorine, mmol/L | 102 ± 5 | 103 ± 5 | 100 ± 3 | 0.03
| Urea nitrogen, mmol/L | 4.9 ± 3.4 | 5.2 ± 3.9 | 4.3 ± 2.1 | 0.47
| Creatinine, µmol/L | 66 (55–80) | 62 (54–79) | 77 (58–83) | 0.16
| ALT, U/L | 32 (21–63) | 20 (13–48) | 55 (28–113) | <0.01
| AST, U/L | 37 (27–62) | 35 (26–48) | 39 (34–150) | 0.08
| Total bilirubin, µmol/L | 14 ± 5 | 12 ± 4 | 17 ± 5 | <0.01
| C-reactive protein, ng/mL | 0.07 | 0.07 | 0.08 | 0.76
| Procalcitonin, ng/mL | (0.04–0.10) | (0.04–0.09) | (0.04–0.19) | |
|HFNC = high flow nasal cannula, NIV = noninvasive ventilation. APACHE II = acute physiologic and chronic health evaluation II, SOFA = sequential organ failure assessment, ALT = alanine aminotransferase, AST = aspartate aminotransferase. * p < .05 for comparison between HFNC and NIV.

### Table 2
The settings of HFNC and NIV

| 1–2 h | 12 h | 24 h |
|-------|------|------|
| HFNC | Flow, L/min | 30 (34–35) | 35 (34–35) | 34 (34–35) |
| | FiO2, % | 40 (40–46) | 40 (40–46) | 40 (35–42) |
| | NIV | Use of CPAP mode, % | 4 (3%) | 3 (3%) | 3 (3%) |
| | Respiratory rate (above zero), cmH2O | 12 (12–15) | 12 (12–15) | 12 (12–16) |
| | PEEP, CPAP, cmH2O | 6 (6–9) | 6 (6–9) | 6 (6–10) |
| | FiO2, % | 40 (40–50) | 40 (40–48) | 40 (40–49) |
|HFNC = high flow nasal cannula, NIV = noninvasive ventilation, CPAP = continuous positive airway pressure, PEEP = positive end expiratory pressure.

### Table 3
Vital signs and arterial blood gas tests at baseline, 1–2 h, 12 h, and 24 h of intervention.

| 1–2 h | Baseline | | HFNC | NIV | p |
|-------|----------|------|------|-----|---|
| N = 23 | N = 13 | | |
| Heart rate, beats/min | 89 ± 16 | 89 ± 16 | 0.99 | | |
| Mean arterial pressure, mmHg | 90 ± 12 | 91 ± 7 | 0.77 | | |
| pH | 7.44 ± 0.04 | 7.47 ± 0.07 | 0.19 | | |
| PaCO2, mmHg | 35 ± 5 | 35 ± 5 | 0.74 | | |
| PaO2/FiO2, mmHg | 196 ± 46 | 165 ± 48 | 0.06 | | |
| NIV as rescue therapy | 1 (4%) | 3 (15%) | >0.99 | | |
| 12 h | Baseline | | HFNC | NIV | p |
|-------|----------|------|------|-----|---|
| N = 23 | N = 13 | | |
| Heart rate, beats/min | 88 ± 18 | 85 ± 16 | 0.57 | | |
| Mean arterial pressure, mmHg | 89 ± 9 | 90 ± 6 | 0.49 | | |
| pH | 7.45 ± 0.04 | 7.48 ± 0.05 | 0.07 | | |
| PaCO2, mmHg | 36 ± 5 | 35 ± 4 | 0.59 | | |
| PaO2/FiO2, mmHg | 210 ± 84 | 211 ± 78 | 0.97 | | |
| HFNC = high flow nasal cannula, NIV = noninvasive ventilation. * p < .05 for comparison between HFNC and NIV.

### Table 4
Outcomes

| 1–2 h | Baseline | | HFNC | NIV | p |
|-------|----------|------|------|-----|---|
| N = 23 | N = 13 | | |
| Duration of HFNC, days | 3.6 (1.6–8.4) | 7.0# | | | |
| Duration of NIV, days | 5.1 (2.3–7.5) | 6.8 (4.5–10.0) | 0.26 | | |
| Duration of HFNC + NIV, days | 7.1 (3.5–12.2) | 7.3 (5.3–10.0) | 0.67 | | |
| HFNC as rescue therapy, % | 1 (8%) | | | | |
| NIV as rescue therapy, % | 10 (43%) | | | | |
| Intubation, % | 4 (17%) | 2 (15%) | >0.99 | | |
| Mortality, % | 1 (4%) | 1 (8%) | >0.99 | | |
|HFNC = high flow nasal cannula, NIV = noninvasive ventilation. *only one patient used HFNC due to NIV intolerance.
Nearly half of the patients who used HFNC as first-line therapy were transitioned to NIV as a rescue therapy. However, only fewer patients who used NIV as a first-line therapy were transitioned to HFNC. The intubation rate and mortality were relatively low. The duration of HFNC + NIV, intubation rate and mortality did not differ between the two groups. Among all the patients, C-reactive protein was independently associated with intubation. And it had high distinguishing power to predict intubation.

In China, use of HFNC ranged from 21% to 31% (pooled incidence: 26%) among the critically ill patients, and the use of NIV ranged from 14% to 37% (pooled incidence: 28%) [6,19,20]. However, the use of HFNC and NIV were largely different between China and other countries. In Lombardy Region, Italy, NIV was used in 11% of ICU patients but no patients used HFNC [7]. In Seattle Region, USA, the HFNC was used in 42% of critically ill patients but none used NIV [8]. Maybe, the availability of the HFNC and NIV, and suggestions or recommendations made by experts or consensus were various between different countries.

In China, the experts have suggested that the HFNC and NIV can be used in COVID-19 patients with PaO₂/FiO₂ ≥ 150 mmHg, and NIV can be cautiously used in those with PaO₂/FiO₂ between 100 and 150 mmHg [13,14]. The Asian Critical Care Clinical Trials Group has suggested that the HFNC and NIV only can be used in COVID-19 patients with mild acute respiratory distress syndrome (ARDS) [21]. The Surviving Sepsis Campaign COVID-19 subcommittee (most of the experts came from Europe and USA) has suggested that the HFNC is superior to NIV in COVID-19 patients with acute hypoxemic respiratory failure, and the NIV can be tried with close monitoring if the HFNC is unavailable [22]. However, most of the recommendations were based on the experts’ suggestion. The level of evidence is weak. To the best of our knowledge, there were no studies to focus on the use of HFNC or NIV in COVID-19 patients except our previous one paper [10]. Different with the experts’ suggestions, 10 patients (17% in HFNC and 46% in NIV) with PaO₂/FiO₂ between 100 and 150 mmHg have used HFNC or NIV as a first-line therapy. And among all the patients, the duration of HFNC + NIV, intubation rate and mortality were similar between two groups. These data provide an important reference for clinical physicians to select respiratory support device on patients with COVID-19.

Among all the patients who used NIV as first-line therapy, the intubation rate was 92% in patients with Middle East respiratory syndrome, 30% in patients with severe acute respiratory syndrome, and 59% in patients with influenza pneumonia [23-25]. In hypoxemic patients whose respiratory failure caused by other reasons, the intubation rate was 36% [26]. However, in our study, the intubation rate was only 15% in COVID-19 patients who used NIV as a first-line intervention. Among the patients who used NIV as a rescue therapy, the intubation rate was 20%. And no medical staff in our study was infected by the airborne transmission. Therefore, the NIV is an alternative respiratory support for COVID-19 patients but all safety measures should be taken.

Early identification of the high-risk patients and early application of intubation decreased mortality [27]. On the contrary, delayed intubation significantly lead to mortality increase both in patients with HFNC and NIV [28,29]. In our study, we found that the C-reactive protein collected at the initiation of HFNC or NIV had high distinguishing power to predict intubation. Therefore, HFNC and NIV should be cautiously used in patients with high level of C-reactive protein. Close monitoring should be taken to avoid delayed intubation.

### Table 6

| Univariate analysis | p |
|---------------------|---|
| Univariate analysis | p |
| Age, years | 1.08 (1.00–1.16) | 0.05 |
| APACHE II score | 1.28 (1.03–1.59) | 0.02 |
| SOFA score | 2.23 (1.10–4.52) | 0.03 |
| Neutrophil percentage, % | 0.87 (0.76–1.00) | 0.04 |
| Platelet counts | 0.96 (0.92–1.00) | 0.04 |
| C-reactive protein, mg/L | 1.04 (1.01–1.07) | <0.01 |
| Respiratory rate at baseline, breaths/min | 1.16 (0.98–1.36) | 0.08 |
| Mean arterial pressure at baseline, mmHg | 0.89 (0.79–1.00) | 0.05 |

OR = odds ratio, CI = confidence interval, APACHE II = acute physiology and chronic health evaluation II, SOFA = sequential organ failure assessment.
Fear of aerosolized transmission was the major problem during the use of HFNC or NIV in COVID-19 patients. In theory, NIV generates more aerosols than HFNC as NIV usually generates higher pressure than HFNC [30]. In our study, use of HFNC and NIV was in the negative pressure ward or ICU, adequate protective supplies (N95 respirator, eye protector, disposable gown, disposable surgical gloves, disposable shoe covers, etc.) were provided to all the medical staff, and strict training was applied before contact with the COVID-19 patients. Therefore, no medical staff got nosocomial infection who managed the critically ill patients in our study. Our experience provides a reference on the prevention and control of nosocomial infection when the HFNC or NIV was used in COVID-19 patients.

This study has several limitations. First, this is a retrospective study, the use of HFNC and NIV was mainly decided based on the experts’ suggestions and the physicians’ experience. Second, we only enrolled 39 patients in our study. The small sample size may skew the results. Further, studies with larger sample size are required to confirm our results. Third, the median time from initiation of HFNC or NIV to intubation was 8.4 days. As intubation beyond 1–2 days after the initiation of HFNC or NIV is associated with increased mortality [27-29], delayed intubation may occur in our study. Close monitoring is needed to avoid delayed intubation.

5. Conclusions

In critically ill patients with COVID-19, the duration of HFNC + NIV, intubation rate and mortality did not differ between patients who used HFNC and NIV as a first-line therapy. Among all the patients, C-reactive protein was independently associated with intubation. And it had high distinguishing power to predict intubation. In addition, no medical staff got nosocomial infection in our study who managed the HFNC and NIV patients with COVID-19.

Authors’ contributions

JD and KW conceived the study, and joined in data collection, data analysis, data interpretation and manuscript preparation, and take responsibility for the content of the manuscript. BXC, XYL, WWS, WZ, JL, YSL, YLH and LFP joined in data collection, data analysis, data interpretation and manuscript preparation. All the authors revised the manuscript and approved the final revision.

Declaration of Competing Interest

We declare that we have no competing interests.
Acknowledgments

This study was supported by special project for emergency clinical research on novel coronavirus pneumonia in Chongqing Medical University (No.13).

References

[1] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. 2019. N Engl J Med. 2020;382(7):279–33.
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
[3] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.
[4] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.
[5] Cao Y, Liu X, Xiong L, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25822.
[6] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
[7] Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.5394.
[8] Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020;382:1199–207.
[9] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. http://www.nhc.gov.cn/wjw/index.shtml.
[10] Wang K, Zhao W, Li J, et al. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10:37.
[11] Keenan SP, Sinufit T, Burns KE, et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. CM AJ. 2011;1:138;E195–214.
[12] Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50.
[13] Critical care committee of Chinese Association of Chest Physician. Conventional respiratory support therapy for Severe Acute Respiratory Infections (SARI): Clinical indications and nosocomial infection prevention and control. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:189–94.
[14] Yuan X, Mu JS, Mo GX, et al. Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:177–80.
[15] Respiratory & Critical Care Medicine Group of Chinese Thoracic Society. Expert consensus of high flow nasal cannula oxygen therapy on clinical application regularity. Zhonghua Jie He He Hu Xi Za Zhi. 2019;42:83–91.
[16] Society of Critical Care Medicine of Chinese Medical Association. Practical guidelines for mechanical ventilation (2006). Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007;19:65–72.
[17] Branson RD, Hess DR, Chatburn RL. Respiratory care equipment. Philadelphia: J.B. Lippincott Company; 1995: 55–62.
[18] Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.
[19] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1096–12.
[20] Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202002-0445oc.
[21] Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30161-2.
[22] Alhazzani W, Moller MH, Alarbi YM, et al. Surviving Sepsis campaign: guidelines on the Management of Critically ill Adults with Coronavirus disease 2019 (COVID-19). Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004363.
[23] Alraddadi BM, Qusmaq I, Al-Hameed FM, et al. Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respi Viruses. 2019;13:382–90.
[24] Cheung TM, Yam LY, So LK, et al. Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. Chest. 2004;126:845–50.
[25] Maciasso JR, Perez M, Almirall J, et al. Early non-invasive ventilation treatment for severe influenza pneumonia. Clin Microbiol Infect. 2013;19:249–56.
[26] Duan J, Chen L, Liang G, et al. Noninvasive ventilation failure in patients with hypoxemic respiratory failure: the role of sepsis and septic shock. Thor Adv Respir Dis. 2019;13:175346691888124.
[27] Duan J, Han X, Bai L, et al. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. Intensive Care Med. 2017;43:192–9.
[28] Kang BJ, Koh Y, Lim CM, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015;41:623–32.
[29] Carrillo A, Gonzalez-Diaz G, Ferrer M, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med. 2012;38:458–66.
[30] Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019;53:1802339.